| 摘要 |
<p>2121235 9307900 PCTABS00021 In vitro treatment of a kidney prior to transplantation into a human recipient to reduce the risk of rejection, comprises perfusing the kidney with a solution of antibody specific to passenger leukocytes (e.g. anti-CD45 antibody) under cold ischaemia (CI) conditions with the renal vein occluded, and incubating the perfused kidney under CI conditions for at least 20 minutes. The volume of perfusion liquid is preferably at least 50 ml and the concentration of mAb about 40 .mu.g/ml or more. This has been found to increase mAb uptake by the target cells and the extent of mAb saturation of the target cells, and seems to be associated with a reduced incidence of graft rejection.</p> |
